The decision to exclude the standard-of-care chemotherapy docetaxel was driven by its variable real-world use, fears it would hinder patient recruitment, and the challenge of timing PARP inhibitor therapy post-chemo. This prioritized a "clean" trial design over including every possible therapy.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

The selection between PARP inhibitors like olaparib and niraparib is not one-size-fits-all. It's a personalized decision based on patient preference for dosing frequency (once vs. twice daily), tolerance for side effects like hypertension, and potential drug-drug interactions.

If lutetium-PSMA is approved and used upfront in hormone-sensitive disease, clinicians may become more comfortable with radioligands generally. This could lead them to use the enzalutamide-radium combination more frequently later on, paradoxically increasing radium's use by flipping the current treatment sequence.

A drug-drug interaction study found that apalutamide induces an enzyme (CYP3A4) that lowers relagolix concentrations, leading to suboptimal hormonal suppression. To maintain efficacy when used in combination, the standard dose of the oral GnRH antagonist relagolix must be doubled.

Though cross-trial comparisons are imperfect, Grade 3+ anemia rates offer a stark contrast between approved PARP+ARPI combinations. The rate was 16% for olaparib+abiraterone (PROPEL) versus a much higher 49% for talazoparib+enzalutamide (TALAPRO-2). This suggests toxicity profiles should be a key factor in treatment selection.

Unlike a competing trial's marginal benefit (HR 0.8) for non-BRCA HRR patients, TALAPRO-3 demonstrated a clinically meaningful hazard ratio of 0.56. This superior performance could lead clinicians to strongly favor the talazoparib combination for this specific and often debated patient population.

Clinical trials combining potent ARPIs like abiraterone and enzalutamide have consistently failed. Once the androgen receptor pathway is maximally suppressed by one agent, adding another with a similar mechanism provides no further clinical advantage, much like hammering a nail that is already flush with the wood.

The BRCA-Way trial showed a combination of abiraterone and olaparib was effective. However, its relevance is limited as many patients now receive abiraterone upfront. The next-generation TALENT trial is designed specifically to address this, testing if re-challenging with an AR-pathway inhibitor alongside a PARP inhibitor is beneficial, demonstrating how trial design must constantly evolve to answer questions raised by new standards of care.